Eli Lilly and Company

James Lincoln Wallis

Jorge Alsina-Fernandez

Hongchang Qu

Tamer Coskun

Milata Mary Abraham

Robert Chadwick Cummins

Robert Andrew Brown

Over Cabrera

Mohamed ElSayed Hamed Elsayed

Amita Datta-Mannan

Xianyin Lai

Incretin analogs are provided that have activity at each of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as type 2 diabetes mellitus, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and obesity.

Incretin analogs and uses thereof

The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus ('T2DM'). Also, the compounds may be useful in the treatment of obesity.

GIP/GLP1 co-agonist compounds

Growing community of inventors

Indianapolis, IN, United States of America

James Lincoln Wallis